Base case utility values and sources.

±Beta(n, N).+The baseline utility for stable HNSCC (with no or mild AE) was 0.65. We derived the utility for each stable HNSCC state with severe cetuximab-related adverse event (grade 3or 4) by applying utility reduction estimates associated with each severe event to the baseline utility value for stable HNSCC. Thus, the utility of stable HNSCC with a specific severe cetuximab-related adverse event is estimated as 0.65− 0.65 × (utility reduction associated with a severe cetuximab-related adverse event), consistent with methodology described by Fryback et al [31].